Literature DB >> 18813919

Proteolysis of prion protein by cathepsin S generates a soluble beta-structured intermediate oligomeric form, with potential implications for neurotoxic mechanisms.

Oxana Polyakova1, Denise Dear, Igor Stern, Stephen Martin, Elizabeth Hirst, Suleman Bawumia, Angus Nash, Guy Dodson, Igor Bronstein, Peter M Bayley.   

Abstract

Formation of PrP aggregates is considered to be a characteristic event in the pathogenesis of TSE diseases, accompanied by brain inflammation and neurodegeneration. Factors identified as contributing to aggregate formation are of interest as potential therapeutic targets. We report that in vitro proteolysis of ovine PrP(94-233) (at neutral pH and in the absence of denaturants) by the protease cathepsin S, a cellular enzyme that also shows enhanced expression in pathogenic conditions, occurs selectively in the region 135-156. This results in an unusually efficient, concentration-dependent conformational conversion of a large subfragment of PrP(94-233) into a soluble beta-structured oligomeric intermediate species, that readily forms a thioflavin-T-positive aggregate. N-terminal sequencing of the proteolysis fragments shows the aggregating species have marked sequence similarities to truncated PrP variants known to confer unusually severe pathogenicity when transgenically expressed in PrP(o/o) mice. Circular dichroism analysis shows that PrP fragments 138-233, 144-233 and 156-233 are significantly less stable than PrP(94-233). This implies an important structural contribution of the beta1 sequence within the globular domain of PrP. We propose that the removal or detachment of the beta1 sequence enhances beta-oligomer formation from the globular domain, leading to aggregation. The cellular implications are that specific proteases may have an important role in the generation of membrane-bound, potentially toxic, beta-oligomeric PrP species in pre-amyloid states of prion diseases. Such species may induce cell death by lysis, and also contribute to the transport of PrP to neuronal targets with subsequent amplification of pathogenic effects.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18813919     DOI: 10.1007/s00249-008-0371-3

Source DB:  PubMed          Journal:  Eur Biophys J        ISSN: 0175-7571            Impact factor:   1.733


  43 in total

1.  Aggregation and fibrillization of the recombinant human prion protein huPrP90-231.

Authors:  W Swietnicki; M Morillas; S G Chen; P Gambetti; W K Surewicz
Journal:  Biochemistry       Date:  2000-01-18       Impact factor: 3.162

2.  Sequential generation of two structurally distinct ovine prion protein soluble oligomers displaying different biochemical reactivities.

Authors:  Human Rezaei; Frédéric Eghiaian; Javier Perez; Bénédicte Doublet; Yvan Choiset; Thomas Haertle; Jeanne Grosclaude
Journal:  J Mol Biol       Date:  2005-04-01       Impact factor: 5.469

Review 3.  Prions and their partners in crime.

Authors:  Byron Caughey; Gerald S Baron
Journal:  Nature       Date:  2006-10-19       Impact factor: 49.962

4.  Mapping the early steps in the pH-induced conformational conversion of the prion protein.

Authors:  D O Alonso; S J DeArmond; F E Cohen; V Daggett
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-27       Impact factor: 11.205

5.  Estimation of globular protein secondary structure from circular dichroism.

Authors:  S W Provencher; J Glöckner
Journal:  Biochemistry       Date:  1981-01-06       Impact factor: 3.162

6.  On the mechanism of alpha-helix to beta-sheet transition in the recombinant prion protein.

Authors:  M Morillas; D L Vanik; W K Surewicz
Journal:  Biochemistry       Date:  2001-06-12       Impact factor: 3.162

Review 7.  Molecular basis of cerebral neurodegeneration in prion diseases.

Authors:  Jörg Tatzelt; Hermann M Schätzl
Journal:  FEBS J       Date:  2007-02       Impact factor: 5.542

Review 8.  A beta oligomers - a decade of discovery.

Authors:  Dominic M Walsh; Dennis J Selkoe
Journal:  J Neurochem       Date:  2007-02-05       Impact factor: 5.372

9.  Synthetic mammalian prions.

Authors:  Giuseppe Legname; Ilia V Baskakov; Hoang-Oanh B Nguyen; Detlev Riesner; Fred E Cohen; Stephen J DeArmond; Stanley B Prusiner
Journal:  Science       Date:  2004-07-30       Impact factor: 47.728

Review 10.  Neuronal and microglial cathepsins in aging and age-related diseases.

Authors:  Hiroshi Nakanishi
Journal:  Ageing Res Rev       Date:  2003-10       Impact factor: 10.895

View more
  3 in total

1.  Cathepsin S increases tau oligomer formation through limited cleavage, but only IL-6, not cathespin S serum levels correlate with disease severity in the neurodegenerative tauopathy progressive supranuclear palsy.

Authors:  Georg Nübling; M Schuberth; K Feldmer; A Giese; L M Holdt; D Teupser; S Lorenzl
Journal:  Exp Brain Res       Date:  2017-05-10       Impact factor: 1.972

2.  Cardiac glycoside-mediated turnover of Na, K-ATPases as a rational approach to reducing cell surface levels of the cellular prion protein.

Authors:  Mohadeseh Mehrabian; Xinzhu Wang; Shehab Eid; Bei Qi Yan; Mark Grinberg; Murdock Siegner; Christopher Sackmann; Muhammad Sulman; Wenda Zhao; Declan Williams; Gerold Schmitt-Ulms
Journal:  PLoS One       Date:  2022-07-01       Impact factor: 3.752

3.  Raft-based interactions of gangliosides with a GPI-anchored receptor.

Authors:  Naoko Komura; Kenichi G N Suzuki; Hiromune Ando; Miku Konishi; Machi Koikeda; Akihiro Imamura; Rahul Chadda; Takahiro K Fujiwara; Hisae Tsuboi; Ren Sheng; Wonhwa Cho; Koichi Furukawa; Keiko Furukawa; Yoshio Yamauchi; Hideharu Ishida; Akihiro Kusumi; Makoto Kiso
Journal:  Nat Chem Biol       Date:  2016-04-04       Impact factor: 15.040

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.